Liberum Capital Raises PureTech Health (LON:PRTC) Price Target to GBX 490
PureTech Health (LON:PRTC) had its price objective increased by Liberum Capital from GBX 450 ($5.54) to GBX 490 ($6.03) in a research note published on Wednesday morning, Stock Target Advisor reports. Liberum Capital currently has a buy rating on the stock.
Other analysts have also recently issued reports about the company. Peel Hunt reiterated a buy rating and issued a GBX 480 ($5.91) price objective on shares of PureTech Health in a research note on Tuesday, June 2nd. Peel Hunt reiterated a buy rating on shares of PureTech Health in a research note on Wednesday, July 8th.
Shares of LON PRTC opened at GBX 272 ($3.35) on Wednesday. The stock has a market cap of $776.59 million and a P/E ratio of 1.88. The company has a current ratio of 1.21, a quick ratio of 1.18 and a debt-to-equity ratio of 6.04. PureTech Health has a 12-month low of GBX 2.11 ($0.03) and a 12-month high of GBX 339.36 ($4.18). The business’s fifty day simple moving average is GBX 272.93 and its 200-day simple moving average is GBX 269.86.
About PureTech Health
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.